Literature DB >> 17443699

Health related quality of life in patients with dystonia and their caregivers in New Zealand and Australia.

Vanessa K Lim1.   

Abstract

Health Related Quality of Life (HRQL) was assessed by the SF-36 in a group of patients with dystonia in New Zealand and Australia. The caregivers of these people were also asked to participate. Low scores from the SF-36 indicate a disability or limitation in HRQL. Compared with the national norms of the respective countries, the participants with dystonia for both countries were significantly lower in the eight dimensions of the SF-36, suggesting that patients with dystonia have lower HRQL compared with their respective national norms without dystonia. In contrast to the patients with dystonia, caregivers did not show lower HRQL scores than their national norms, suggesting that while dystonia affects the HRQL of those with the disorder, their caregivers may be less affected. Descriptive and demographic information were also gathered and are discussed. An important factor that may affect the HRQL of patients with dystonia is the length of time required to be diagnosed in this sample and the number of medical practitioners the patients consulted prior to a confirmed diagnosis. (c) 2007 Movement Disorder Society.

Entities:  

Mesh:

Year:  2007        PMID: 17443699     DOI: 10.1002/mds.21486

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  5 in total

1.  Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives.

Authors:  Dursun Ceylan; Sevda Erer; Mehmet Zarifoğlu; Nevin Türkeş; Güven Özkaya
Journal:  Neurol Sci       Date:  2019-01-18       Impact factor: 3.307

2.  The role of the trigeminal sensory nuclear complex in the pathophysiology of craniocervical dystonia.

Authors:  Lynley Bradnam; Christine Barry
Journal:  J Neurosci       Date:  2013-11-20       Impact factor: 6.167

3.  A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.

Authors:  Joohi Jimenez-Shahed
Journal:  Neuropsychiatr Dis Treat       Date:  2011-12-23       Impact factor: 2.570

4.  Quality of life in isolated dystonia: non-motor manifestations matter.

Authors:  Johanna Junker; Brian D Berman; James Hall; Deena W Wahba; Valerie Brandt; Joel S Perlmutter; Joseph Jankovic; Irene A Malaty; Aparna Wagle Shukla; Stephen G Reich; Alberto J Espay; Kevin R Duque; Neepa Patel; Emmanuel Roze; Marie Vidailhet; H A Jinnah; Norbert Brüggemann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-02-09       Impact factor: 13.654

Review 5.  Behavioural interventions for people living with adult-onset primary dystonia: a systematic review.

Authors:  C J Bernstein; D R Ellard; G Davies; E Hertenstein; N K Y Tang; M Underwood; H Sandhu
Journal:  BMC Neurol       Date:  2016-03-22       Impact factor: 2.474

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.